On Mar. 26, 2020, iBio announced that it had entered into a development agreement with AzarGen Biotechnologies. Signed in 2018, the agreement contemplates initial contract development and manufacturing of AzarGen’s biosimilars at iBio’s Bryan, Texas facility.

Ultimately, iBio planned to transfer its proprietary FastPharming Manufacturing System to AzarGen in South Africa for production of critical biological medicines for the African continent.